List view / Grid view
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
13 January 2016 | By Oxford Global
In anticipation of our Proteins and Antibodies Congress, Bernardo Perez-Ramirez spoke to us about his research and his expectations...
In this eBook you will learn how to shorten cell line development time and deliver stable clones with higher affinities and expression levels....
18 December 2015 | By Victoria White
OMT has leading antibody drug discovery technology and is believed to be the only company in the world offering three transgenic animal platforms for license...
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
The success story of Mapp Pharmaceuticals’ experimental drug, ZMapp, during last year’s Ebola outbreak highlights the potential of plant-made monoclonal antibodies (mAbs) as life-saving treatments.
27 October 2015 | By Victoria White
Using its proprietary True Human technology, the Company has begun screening human blood samples from donors to identify and clone a therapeutic antibody candidate...
20 October 2015 | By Victoria White
The surprise finding could lead to a powerful new therapy for leukaemia and possibly other cancers...
12 October 2015 | By Victoria White
As part of the expanded collaboration, Innovent could receive additional milestones totalling more than $1 billion if the products reach certain milestones...
29 September 2015 | By Victoria White
LA Cell has exclusively licensed technology that enables modified monoclonal antibodies to penetrate into cells and target "undruggable" disease-causing molecules...
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
25 August 2015 | By Victoria White
MorphoSys and Immatics have formed an alliance to generate antibody-based therapeutics against multiple proprietary cancer antigens recognised by T cells...
18 August 2015 | By The European Antibody Congress
The European Antibody Congress takes place 9-11 November 2015 at the Congress Centre, Basel...
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Twelve new treatments, diagnostics and medical technologies will receive funding from the eighth round of the successful Biomedical Catalyst (BMC)...
4 August 2015 | By Victoria White
MorphoSys and G7 Therapeutics have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs)...
